Biopharma EHS
This episode is a test use case where you can take a very technical scientific document and upload to a large language model to create a two-host podcast. The results were amazing.
info_outlineBiopharma EHS
In this episode, Dean Calhoun of Affygility Solutions discusses top 10 mistakes & tricks used by cheap providers of PDE reports.
info_outlineBiopharma EHS
Interview with Mark Cunningham-Hill where we will discuss the coronavirus and precautions that business travelers should take and other precautions in general when traveling on business internationally.
info_outlineBiopharma EHS
In this episode, Dean Calhoun of Affygility Solutions interviews Dave Eherts, Vice President of Global EHS for Allergan. In this 25 minute interview we discuss a wide variety of EH&S issues that Dave was involved in over his 30+ years in EHS. These issues include managing the financial aspects of EHS, potent compound safety and the challenges with occupational exposure limits for pharmaceuticals, and other career advice for EH&S professionals.
info_outlineBiopharma EHS
For July 20, 2017. Artificial Intelligence is about to play a major role in the pharmaceutical industry. On July 2nd of this year, Glaxo-Smith-Kline revealed a 43-million dollar deal in which they will use A.I. to make the process of discovering new drugs easier. The goal is to reduce the time it takes from identifying a target for disease intervention to finding a molecule that acts against it. He hopes to bring it from an average 5 and a half years today to just one year in the very near future.
info_outlineBiopharma EHS
Occupational Toxicology and Occupational Medicine - Where are they the same and where are they different? In this episode of the BioPharma EHS Podcast, Dean M. Calhoun, President and CEO of Affygility Solutions hosts a discussion between Dr. Mark Cunningham-Hill, President of Worldwide Health Consulting LLC and Dr. Frank Richardson, Principal Toxicologist for LLC. The discussion starts out covering the basic elements of an occupational medicine program and the unique challenges posed by the pharmaceutical industry in which occupational exposure to potent compounds can cause adverse effects in...
info_outlineBiopharma EHS
In Episode #24 of the Biopharma EHS podcast, Dean M. Calhoun, CIH discusses with Dr. Joe Nieusma, Senior Occupational Toxicologist for Affygility Solutions, the "Mystery of Cytotoxic Compounds." For multi-product pharmaceutical manufacturing facilities, this often a controversial topic since many people believe that cytotoxic compounds require dedicated facilities or equipment. It is also a topic of debate when setting occupational exposure limits and acceptable daily exposure values for active pharmaceutical ingredients.
info_outlineBiopharma EHS
In this episode of the Biopharma EHS podcast, Dean M. Calhoun, CIH, President and CEO of Affygility Solutions interviews Kevin Rosenthal of . During the interview we discuss handling potent compounds, , and occupational control banding.
info_outlineBiopharma EHS
In this episode of the Biopharma EHS Podcast, Dean M. Calhoun, CIH, President and CEO of , interviews Ms. Stephanie Wilkins, President of , on the subject of Risk-MaPP, ADEs and PDEs: Their importance to multi-product pharmaceutical manufacturing facilities. Risk-MaPP stands for Risk-Based Manufacture of Pharmaceutical Products. It is one of the International Society of Pharmaceutical Engineers' (ISPE) Base-line Guides. One of the essential components of Risk-MaPP is the determination of acceptable daily exposure (ADE) values. Calculation of ADEs is similar to the calculation of PDEs presented...
info_outlineBiopharma EHS
BioPharma EH&S Podcast Episode No. 20...
info_outlineNanotechnology and the Pharmaceutical Industry - an interview with Don Ewert of OSO Biopharmaceuticals.
Hello everybody and welcome back to another episode of the BioPharma EH&S Podcast, my name is Dean Calhoun of Affygility Solutions and this is the podcast dedicated to discussing critical environmental, health and safety issues facing the biopharma industry, helping you take your environmental, health and safety programs to the next level.
Overview
I’ll briefly cover what we talked about last time in episode number 17
And finally, we’ll discuss upcoming events and happenings of importance to environmental, health and safety professionals in the BioPharma Industry.
So, without further delay, let’s go ahead get started. Last time in Episode number 17 we discussed the topic of “Containment Validation and Surrogate Monitoring.” In that Podcast, Matt Meiners, Laboratory Services Manager for Bureau Veritas and I discussed what is surrogate monitoring, some of the key factors to consider when selecting a surrogate compound, and finally, what are some of the common mistakes that occur when performing containment validation and surrogate monitoring. It was a great interview, and I appreciate Matt taking the time out of his busy schedule to participate. If that’s something that may interest you, I would suggest that you go back and listen to Episode 17.
Alright, let’s now move on to our main topic for today which is an interview with Don Ewert, Environmental, Health and Safety Manager on nanotechnology. I should mention ahead of time, that this section of the podcast was recorded on January 19th, 2012 via Skype. There is a few instances where we have a Skype garble moment, so I do apologize in advance for that. So without further delay, here we go.
[audio portion]
The next event that I would like to mention is the annual Society of Toxicology conference to be held on March 11th through 15th in San Francisco. Affygility Solutions won’t be exhibiting at this conference, but our Senior Toxicologist, Joe Nieusma, may be attending. If you would like more information on this conference go to the Society of Toxicology’s website at sot.org
That does it for this week’s show. We look forward to having you listen in next time.
About Affygility Solutions. Affygility Solutions provides environmental, health and safety software and services to the pharmaceutical, biotechnology, and medical device industry.